NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis $1.75 -0.07 (-3.85%) (As of 10/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Marinus Pharmaceuticals Stock (NASDAQ:MRNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$1.72▼$1.8450-Day Range$1.10▼$1.9052-Week Range$1.05▼$11.26Volume648,868 shsAverage Volume1.08 million shsMarket Capitalization$96.13 millionP/E RatioN/ADividend YieldN/APrice Target$8.83Consensus RatingModerate Buy Company OverviewMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Marinus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreMRNS MarketRank™: Marinus Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 177th out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Marinus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.93) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Marinus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.86% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 11.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.55 Percentage of Shares Shorted5.86% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 11.03%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Marinus Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest4 people have searched for MRNS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,433.00 in company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. MRNS Stock News Headlines3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity (MRNS)Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.October 11, 2024 | marketbeat.comWill Marinus Pharmaceuticals Be the Next Big Winner in Biotech?Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.October 1, 2024 | marketbeat.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.October 22, 2024 | Crypto Swap Profits (Ad)Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® PatentOctober 22 at 7:30 AM | msn.comMarinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration RegimensOctober 15, 2024 | businesswire.comMarinus Pharmaceuticals to Present New Epilepsy Treatment Data at Upcoming ConferenceOctober 15, 2024 | msn.comMarinus Pharmaceuticals Issues Stock Options to New EmployeeOctober 15, 2024 | msn.comMarinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual MeetingOctober 9, 2024 | finance.yahoo.comSee More Headlines MRNS Stock Analysis - Frequently Asked Questions How have MRNS shares performed this year? Marinus Pharmaceuticals' stock was trading at $10.87 at the beginning of the year. Since then, MRNS stock has decreased by 83.9% and is now trading at $1.75. View the best growth stocks for 2024 here. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company had revenue of $8.06 million for the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 7,831.35% and a negative net margin of 493.14%. When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals shares reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/13/2024Today10/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$8.83 High Stock Price Target$13.00 Low Stock Price Target$3.00 Potential Upside/Downside+409.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-493.14% Pretax Margin-493.14% Return on Equity-7,831.35% Return on Assets-98.83% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.15 Sales & Book Value Annual Sales$30.26 million Price / Sales3.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book5.60Miscellaneous Outstanding Shares54,934,000Free Float52,076,000Market Cap$95.31 million OptionableOptionable Beta1.14 This page (NASDAQ:MRNS) was last updated on 10/22/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredElection rigged? We caught them red-handed…What happens if NOBODY will be elected the next President of the United States on Nov. 5? Not Donald Trump...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | SponsoredFed Quietly Admits Gold is Replacing the DollarA major shift is occurring in the global financial system… The Fed has "quietly admitted" that Gold is repl...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Marinus Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.